BioXcel CFO exercises RSUs for 35 shares
BioXcel Therapeutics, Inc. Chief Financial Officer Richard I. Steinhart exercised derivative awards tied to company equity.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BioXcel Therapeutics, Inc. Chief Financial Officer Richard I. Steinhart exercised derivative awards tied to company equity. On June 15, 2026, he acquired 35 shares of Common Stock upon conversion of Restricted Stock Units, bringing his direct Common Stock holdings to 26,335 shares. Following the transaction, he also directly held 212 Restricted Stock Units, each representing a contingent right to receive one share of Common Stock under a vesting schedule from a March 15, 2023 grant of 562 RSUs.
Insider Trade Summary
35 shares exercised/converted
Exercise
2 txns
Insider
Steinhart Richard I
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 35 | $0.00 | $0.00 |
| Exercise | Common Stock | 35 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 212 contracts (Direct);
Common Stock — 26,335 shares (Direct)
Footnotes (2)
- F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- F2. On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Key Figures
Shares acquired: 35 shares
Shares held after: 26,335 shares
RSUs remaining: 212 RSUs
+3 more
6 metrics
Shares acquired
35 shares
Common Stock acquired on June 15, 2026 via RSU exercise
Shares held after
26,335 shares
Direct Common Stock holdings following the transaction
RSUs remaining
212 RSUs
Direct Restricted Stock Unit holdings after the transaction
Original RSU grant
562 RSUs
Granted on March 15, 2023
Initial vesting tranche
25%
Vests on first anniversary of March 15, 2023
Quarterly vesting rate
6.25%
Vests at end of each successive three-month period thereafter
Key Terms
Restricted Stock Units, contingent right, vesting, Chief Financial Officer
4 terms
Restricted Stock Units financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock."
vesting financial
"562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Chief Financial Officer financial
"Steinhart Richard I … officer_title: "Chief Financial Officer""
A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did BioXcel Therapeutics (BTAI) report for its CFO?
BioXcel Therapeutics reported that CFO Richard I. Steinhart acquired 35 shares of Common Stock through the exercise of Restricted Stock Units on June 15, 2026. This action converts previously granted RSUs into actual shares under his equity compensation plan.
What Restricted Stock Unit position remains for the BioXcel (BTAI) CFO?
Following the reported transaction, the CFO directly holds 212 Restricted Stock Units. Each RSU represents a contingent right to receive one share of BioXcel Therapeutics Common Stock, subject to the original vesting conditions described in the grant documentation.
What was the original RSU grant reported for the BioXcel (BTAI) CFO?
On March 15, 2023, the CFO was granted 562 Restricted Stock Units. Twenty-five percent vest on the first anniversary of March 15, 2023, and 6.25% vest at the end of each successive three‑month period, subject to his continuous employment with BioXcel Therapeutics.
How do the BioXcel (BTAI) CFO’s RSUs convert into Common Stock?
Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. As RSUs vest under the specified schedule and conditions, they can be settled in shares, as shown by the 35 RSUs converted into 35 Common shares on June 15, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates